Drug Profile
Beclabuvir
Alternative Names: BMS-791325Latest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator Bristol-Myers Squibb
- Class Amides; Antivirals; Azabicyclo compounds; Benzazepines; Cyclohexanes; Cyclopropanes; Heterocyclic compounds with 4 or more rings; Indoles; Organic bridged compounds; Phenyl ethers; Piperazines; Small molecules; Sulfonamides
- Mechanism of Action Hepatitis C virus NS 5 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Hepatitis C
Most Recent Events
- 11 Apr 2014 Bristol-Myers Squibb initiates enrolment in a phase I bioavailability trial in volunteers in United Kingdom (NCT02112110)
- 22 Feb 2014 Discontinued - Phase-I for Hepatitis C in USA (PO) prior to 2014
- 22 Feb 2014 Discontinued - Phase-I/II for Hepatitis C in Argentina (PO) prior to 2014